World Health Organization site
Untitled
Immunization surveillance, assessment and monitoring Monitoring immunization systems and safety Assessing diseases burden and immunization impact Vaccine preventable diseases Data statistics and graphics Guidelines tools and publications
Country selection form
Last update: 10 August 2009
Next overall update: December 2009
 		Immunization Profile - China
Development status: Developing GNI / capita (US$):1 2'940 Infant (under 12 months) mortality rate:2§ 19
GDP / capita (US$):1 5'962 Child (under 5 years) mortality rate:2§ 22
Population data in thousands   3
  2008 2007 2006 2005 2004 2000 1990 1980
Total population 1'337'411 1'329'090 1'320'724 1'312'253 1'303'667 1'266'954 1'142'090 980'929
Live births 18'134 17'993 17'891 17'844 17'867 18'649 24'663 20'511
Surviving infants 17'724 17'577 17'467 17'412 17'424 18'149 23'921 19'570
Pop. less than 5 years 86'881 86'736 86'913 87'458 88'415 95'371 125'165 98'041
Pop. less than 15 years 274'590 278'232 282'903 288'716 295'793 325'823 324'117 348'280
Female 15-49 years 365'457 363'727 361'568 359'099 356'357 343'548 305'634 233'206
Number of reported cases (Click for full incidence time series from 1980 for China)
 
Diphtheria 0 0 1 0 2 19 421 9'767
Japanese encephalitis 2'975 4'330 7'647    -    -    -    -    -
Measles 131'441 109'023 99'602 124'219 70'549 71'093 85'705 1'122'285
Mumps 310'826 252'701 273'242 291'135 226'619    -    -    -
Pertussis 2'387    - 2'595 3'844 4'705 5'561 20'015 613'648
Polio  * 0 0 0 0 2 0 5'065 7'442
Rubella 120'354 74'746 37'137 25'446 24'015    -    -    -
Rubella (CRS)    -    -    -    -    -    -    -    -
Tetanus (neonatal) 1'786 2'112 2'519 2'761 2'954 3'230    -    -
Tetanus (total) 1'786 2'112    - 2'761    -    -    -    -
Yellow fever    -    -    -    - 0    -    -    -
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
Percent of target population vaccinated, by antigen Hovering over an antigen reveals its fuller definition 
  Last coverage survey 4   Official country estimates 5
  (Click for full official coverage time series from 1980 for China)
  Year Result  
BCG 1984 59        EPI 97 94 92 86 99 85 99    -
DTP1 1984       -        EPI 99 94 94 87 99    -    -    -
DTP3 1984 73        EPI 97 93 93 87 99 85 97    -
HepB1 (birth dose)    -    - 91 86 88 86 76    -    -    -
HepB3    -    - 95 92 91 84 90 60    -    -
Hib3    -    -    -    -    -    -    -    -    -    -
JapEnc    -    -    -    -    -    -    -    -    -    -
MCV 1984 84        EPI    - 94 93 86 98 98 98    -
MCV2    -    -    - 92 94 84 96    -    -    -
PCV1    -    -    -    -    -    -    -    -    -    -
PCV3    -    -    -    -    -    -    -    -    -    -
Pol3 1984 84        EPI 99 94 94 87 99 90 98    -
Rota1    -    -    -    -    -    -    -    -    -    -
Rota_last    -    -    -    -    -    -    -    -    -    -
Rubella1    -    -    -    -    -    -    -    -    -    -
TT2plus 1994       -        MICS    -    -    -    -    -    -    -    -
PAB    -    -    -    -    -    -    -    -    -    -
VAD1    -    -    -    -    -    -    -    -    -    -
YFV    -    -    -    -    -    -    -    -    -    -
  WHO-UNICEF coverage estimates.6
  (Click for full WHO-UNICEF coverage estimates time series from 1980 for China)
 
BCG 97 94 92 86 86 85 99    -
DTP1 99 94 94 95 95 95 98    -
DTP3 97 93 93 87 87 85 97    -
HepB3 95 92 91 84 84 72    -    -
Hib3    -    -    -    -    -    -    -    -
MCV 94 94 93 86 86 85 98    -
Pol3 99 94 94 87 87 86 98    -
Number of districts in the country 2,859  
% of coverage reports received at national level
vs number of reports expected 		100  
Proportion of
districts reporting
DTP3 coverage: 		/
|
|
\
Greater or equal to 90%
From 80 to 89% 1
From 50 to 79% 0
Lesser than 50% 0
Proportion of districts not reporting DTP3 coverage 99 %
Immunization Schedule (2008 or latest available) Hovering over an antigen reveals its fuller definition 
Vaccine Schedule
Vaccine Schedule
BCG        birth;  
DT        6 years;  
DTaP        3, 4, 5, 18-24 months;  
DTwP        3, 4, 5, 18-24 months;  
HepA        18 months;  
HepB        birth; 1, 6 months;  
JapEnc        8 months; 2 years;  
 [or 8 months (x2); 2, 6 years;]
MenA        6-18 months (x2);  
MenAC        3, 6 years;  
MM        18-24 months; Part of country
MMR        18-24 months;  
MR        8 months;  
OPV        2, 3, 4 months; 4 years;  
Immunization indicators  
Indicator Expected answer 2008 2007 2006 2005 2004 2003
Planning and management
Multi-year plan (MYP) for immunization Yes/No/NA Yes No No No Yes Yes
What years does the MYP cover? number     NA      
Is MYP costing included? Yes/No/NA Yes   NA      
Was there an annual work plan for immunization services? Yes/No/NA Yes Yes Yes Yes Yes Yes
Annual work plan costing included? Yes/No/NA Yes No No      
Number of districts with microplans that include activities to raise immunization coverage number 2859 3132 3132      
% of districts with microplans to raise immunization coverage From 0 to 100% 100 100 100      
Year of last inventory of all refrigeration equipment assigned for public immunization services. number            
Are data analyzed at the national level to identify poorly performing districts? Yes/No/NA Yes          
Are outreach session performed at district or lower level? Yes/No/NA Yes          
Is supportive supervision with on-site training performed at district or lower level? Yes/No/NA Yes          
Are meeting held with local leaders at district or lower level? Yes/No/NA Yes          
Is local data analysis performed at district or lower level? Yes/No/NA Yes          
Are other activities performed at district or lower level? text            
 
System performance
Total number of districts in country number 3105 3132 3132 3204   2863
% of coverage report received at national level vs number of reports expected From 0 to 100% 100 98 99 97 94  
Nº districts had <50% DTP3 coverage number 0 0 1 1   22
% districts had <50% DTP3 coverage From 0 to 100% 0 0 0 0   1
Nº districts had 50-79% DTP3 number 11 4 7 11   20
% districts had 50-79% DTP3 From 0 to 100% 0 0 0 0   1
Nº districts had 80-89% DTP3 coverage number 22 11 22 22   60
% districts had 80-89% DTP3 coverage From 0 to 100% 1 0 1 1   2
Nº districts had >=80% DTP3 coverage number 3094 3023 3114 3086   2800
% districts had >=80% DTP3 coverage From 0 to 100% 100 97 99 96   98
Nº districts with 90-94% DTP3 coverage number 42          
% of districts had 90-94% DTP3 coverage From 0 to 100% 1          
Nº districts with >=95% DTP3 coverage number 3030          
% of districts with >=95% DTP3 From 0 to 100% 98          
Nº districts had >=90% DTP3 coverage number 3072 3012 3092 3064   2740
% districts had >=90% DTP3 coverage From 0 to 100% 99 96 99 96   96
Nº districts not reporting DTP3 number 0 105 10 106   21
% districts not reporting DTP3 From 0 to 100% 0 3 0 3   0
Nº districts had <50% MCV1 coverage number   0 1 3   11
% districts had <50% MCV1 coverage From 0 to 100%   0 0 0   0
Nº districts had 50-79% MCV1 coverage number   5 11 14   30
% districts had 50-79% MCV1 coverage From 0 to 100%   0 0 0 0 1
Nº districts had 80-89% MCV1 coverage number   23 35 37   60
% districts had 80-89% MCV1 coverage From 0 to 100%   1 1 1 1  
Nº districts had >=80% MCV1 coverage number   3023 3089 3082   2792
% districts had >=80% MCV1 coverage From 0 to 100%   97 99 96   98
Nº districts with 90-94% MCV1 coverage number            
% of districts had 90-94% MCV1 coverage From 0 to 100%            
Nº districts with >=95% measles (MCV1) coverage number            
% of districts with >=95% MCV1 coverage From 0 to 100%            
Nº districts had >=90% MCV1 coverage number   3000 3054 3045   2732
% districts had >=90% MCV1 coverage From 0 to 100%   96 98 95   95
Nº districts not reporting MCV1 number 3105 104 31 105   30
% districts not reporting MCV1 From 0 to 100% 100 3 1 4 99 4
Nº districts had <50% TT2+ (pw) coverage number            
% districts had <50% TT2+ (pw) coverage From 0 to 100%            
Nº districts had 50-79% TT2+ (pw) number           0
% districts had 50-79% TT2+ (pw) From 0 to 100%           0
Nº districts had 80-89% TT2+ (pw) coverage number            
% districts had 80-89% TT2+ (pw) coverage From 0 to 100%            
Nº districts had >=80% TT2+ (pw) coverage number           0
% districts had >=80% TT2+ (pw) coverage From 0 to 100%           0
Nº districts with 90-94% TT2+ coverage number            
% of districts had 90-94% TT2+ (pw) coverage From 0 to 100%            
Nº districts with >=95% TT2+ (pw) coverage number            
% of districts with >=95% TT2+ (pw) From 0 to 100%            
Nº districts had >=90% TT2+ (pw) coverage number            
% districts had >=90% TT2+ (pw) coverage From 0 to 100%            
Nº districts not reporting TT2plus number 3105 3132 3132 3204   2863
% districts not reporting TT2plus From 0 to 100% 100 100 100 100 100 100
Number of districts with >10% DTP drop-out rate number 414 419 346 445 508 225
% of districts had >10% drop-out rates From 0 to 100% 14 13 11 14 18 8
Drop-out rate between DTP1 and DTP3 coverage From 0 to 100% 2 1 1 1 -0.1  
% point difference between HepB3 and DTP3 coverage From 0 to 100% 2 1 2 2 9 2
Is there a vaccine wastage monitoring system at service delivery level? Yes/No/NA            
Formula for wastage calculation text  
 
Surveillance
Is there a surveillance system in place for invasive bacterial diseases Yes/No/NA No          
Is there a surveillance system in place for rotavirus diarrhoea Yes/No/NA            
 
Vaccine supply
Was there any district with vaccine supply interruption? Yes/No         No  
% of districts supplied with sufficient number of AD syringes From 0 to 100%            
 
Vaccine wastage
BCG vaccines wastage number            
National % wastage for DTP From 0 to 100%            
National % wastage for HepB From 0 to 100%         10  
National % wastage for Hib From 0 to 100%            
Pneumococcal conjugate vaccine vaccines wastage number            
Rotavirus vaccines wastage number            
Polio vaccines wastage number            
National % wastage for MCV From 0 to 100%            
Yellow Fever vaccines wastage number            
Tetanus toxoid vaccines wastage number            
 
Safety
Activity workplan for immunization injection safety Yes/No/NA Yes Yes NA Yes ND Yes
Activity workplan for waste management Yes/No/NA Yes NA NA No ND  
Type of injection equipment Ad syringes Yes/No/NA Yes Yes Yes Yes Yes Yes
No. of districts using AD syringes Injection equipment number 2859 1293       1302
Type of injection equipment non AD disposables Yes/No/NA No Yes Yes Yes Yes Yes
No. of districts using Non-AD disposables Injection equipment number 0          
Type of injection equipment Sterilizables Yes/No/NA No No Yes Yes Yes No
No. of districts using Sterilisables Injection equipment number 0          
Are safety boxes distributed with all vaccine deliveries Yes/No/NA     NA No Yes Yes
Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NA Yes Yes Yes Yes No No
How many AEFI were reported? number 20823 8615 6620 1313 0  
How many AEFI were categorized as "serious" adverse events number 541          
National policy regarding disposal: Incineration Yes/No Yes Yes Yes Yes Yes Yes
National policy regarding disposal: Open burning Yes/No No Yes No Yes Yes Yes
National policy regarding disposal: Burial Yes/No No Yes No Yes Yes Yes
National policy regarding disposal: Other Yes/No No Yes No     No
National policy regarding disposal: No policy Yes/No No   No     No
 
Finance
Line item in national budget for vaccines Yes/No/NA Yes NA NA Yes ND Yes
What amount of government funds were spent on vaccines number 2033790000          
Local currency or US$ (government funds on vaccine) text Local currency          
Percentage of routine vaccines funded by Government From 0 to 100%       100   18
Is the percentage of routine vaccine costs financed by the government an estimate Yes/No            
Line item in national budget for injection supply Yes/No/NA Yes     Yes ND Yes
What amount of government funds were spent on routine immunization number 2721260000          
Local currency or US$ (government funds on immunization) text Local currency          
Immunization spend. Financed using Government funds? From 0 to 100% 100          
Is the % of immunization spending financed using Government funds an estimate? Yes/No No          
 
New and under utilized vaccines introduction
Hepatitis B vaccine integrated in routine immunization schedule Yes/Yes [A]/Yes [P]/No Yes Yes Yes Yes Yes Yes
Hib vaccine integrated in routine immunization schedule Yes/Yes [P]/No No No No No No No
Is Measles 2nd dose vaccine integrated into the routine immunization systems? Yes/No/Yes [P] Yes Yes Yes Yes Yes Yes
Mumps vaccine integrated in routine immunization schedule Yes/No Yes Yes(P) No No No No
Pneumococcal vaccine integrated in routine immunization schedule Yes/No/Yes [P]/Yes [R] No No        
Rotavirus vaccine integrated in routine immunization schedule Yes/No/Yes [P]/Yes [R] No No        
Rubella vaccine integrated in routine immunization schedule Yes/No Yes Yes(P) No No No No
 
Maternal and neonatal tetanus (NT) elimination
Protection at birth (PAB) against neonatal tetanus From 0 to 100%            
NT eliminated Yes/No No No No No No No
 
Polio eradication
Non-polio AFP rate number 1.9 1.9 2.1 1.9 1.9 1.5
% adequate specimen From 0 to 100% 90 91 91 88 90 89
Confirmed polio number 0 0 0 0 2 0
 
Vitamin A
Vitamin A deficiency status Subclinical (SC); Clinical (C); Possibility of VAD (NDP); VAD unlikely (NDU) NDP NDP NDP NDP NDP NDP
Were Vitamin A supplements distributed with routine services? Yes/No No No No No Yes Yes
Were Vitamin A supplements integrated with campaigns? Yes/No No No No No No No
 
Yellow Fever
Member states at risk for Yellow Fever Yes/No No No No No No No
Yellow Fever in schedule Yes/High risk/Partial/No No No No No No No
 
Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
1Source: "The 2009 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
2Source: World Health Statistics 2009, data for 2007.
3Source: United Nations, Population Division. The World Population Prospects - the 2008 revision. New York, 2009.
4Source: UNICEF/WHO survey database.
5Source: If no official estimate is available, the administrative coverage is reported. * indicates coverage over 99.5%.
6Source: WHO-UNICEF estimates.

immunization_monitoring_footer
Employment | Other UN Sites | Search | Suggestions | RSS | Privacy
© World Health Organization 2010. All rights reserved